Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Lyell Immunopharma IncCommon Stock stock

Learn how to easily invest in Lyell Immunopharma IncCommon Stock stock.

Lyell Immunopharma, Inc. Common Stock is a biotechnology business based in the US. Lyell Immunopharma IncCommon Stock shares (LYEL) are listed on the NASDAQ and all prices are listed in US Dollars. Lyell Immunopharma IncCommon Stock employs 188 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Lyell Immunopharma IncCommon Stock

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LYEL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Lyell Immunopharma IncCommon Stock stock price (NASDAQ: LYEL)

Use our graph to track the performance of LYEL stocks over time.

Lyell Immunopharma IncCommon Stock shares at a glance

Information last updated 2021-07-28.
52-week range$13.11 - $18.90
50-day moving average $16.00
200-day moving average $16.00
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Lyell Immunopharma IncCommon Stock shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Lyell Immunopharma IncCommon Stock stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lyell Immunopharma IncCommon Stock financials

Revenue TTM $8.9 million
Gross profit TTM $7.8 million
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation $3.3 billion

TTM: trailing 12 months

Shorting Lyell Immunopharma IncCommon Stock shares

There are currently 2.1 million Lyell Immunopharma IncCommon Stock shares held short by investors – that's known as Lyell Immunopharma IncCommon Stock's "short interest". This figure is 57.5% up from 1.3 million last month.

There are a few different ways that this level of interest in shorting Lyell Immunopharma IncCommon Stock shares can be evaluated.

Lyell Immunopharma IncCommon Stock's "short interest ratio" (SIR)

Lyell Immunopharma IncCommon Stock's "short interest ratio" (SIR) is the quantity of Lyell Immunopharma IncCommon Stock shares currently shorted divided by the average quantity of Lyell Immunopharma IncCommon Stock shares traded daily (recently around 777960.6741573). Lyell Immunopharma IncCommon Stock's SIR currently stands at 2.67. In other words for every 100,000 Lyell Immunopharma IncCommon Stock shares traded daily on the market, roughly 2670 shares are currently held short.

To gain some more context, you can compare Lyell Immunopharma IncCommon Stock's short interest ratio against those of similar companies.

However Lyell Immunopharma IncCommon Stock's short interest can also be evaluated against the total number of Lyell Immunopharma IncCommon Stock shares, or, against the total number of tradable Lyell Immunopharma IncCommon Stock shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lyell Immunopharma IncCommon Stock's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Lyell Immunopharma IncCommon Stock shares in existence, roughly 10 shares are currently held short) or 0.2287% of the tradable shares (for every 100,000 tradable Lyell Immunopharma IncCommon Stock shares, roughly 229 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lyell Immunopharma IncCommon Stock.

Find out more about how you can short Lyell Immunopharma IncCommon Stock stock.

Lyell Immunopharma IncCommon Stock share dividends

We're not expecting Lyell Immunopharma IncCommon Stock to pay a dividend over the next 12 months.

Lyell Immunopharma IncCommon Stock overview

Lyell Immunopharma, Inc. , a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845 for multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. .

Stocks similar to Lyell Immunopharma IncCommon Stock

Frequently asked questions

What percentage of Lyell Immunopharma IncCommon Stock is owned by insiders or institutions?
Currently 16.006% of Lyell Immunopharma IncCommon Stock shares are held by insiders and 1.273% by institutions.
How many people work for Lyell Immunopharma IncCommon Stock?
Latest data suggests 188 work at Lyell Immunopharma IncCommon Stock.
When does the fiscal year end for Lyell Immunopharma IncCommon Stock?
Lyell Immunopharma IncCommon Stock's fiscal year ends in December.
Where is Lyell Immunopharma IncCommon Stock based?
Lyell Immunopharma IncCommon Stock's address is: 400 East Jamie Court, South San Francisco, CA, United States, 94080

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site